Drug Search Results
More Filters [+]

Deleobuvir

Alternative Names: deleobuvir, bi-207127, bi 207127, bi207127
Latest Update: 2016-06-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: HCV-NS5B Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Deleobuvir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hepatitis A|Hepatitis C, Chronic|Liver Cirrhosis|Hepatitis C

Phase 2: Hepatitis C, Chronic|Hepatitis A

Phase 1: Hepatitis C, Chronic|Healthy Volunteers|Kidney Diseases|Hepatitis A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01858961

P3

Withdrawn

Hepatitis C, Chronic

2016-07-01

2012-003534-17

P2

Completed

Hepatitis C, Chronic

2016-06-08

2012-003533-41

P3

Completed

Liver Cirrhosis

2015-01-22

HCVerso1

P3

Completed

Hepatitis C, Chronic

2015-01-01

Recent News Events

Date

Type

Title